Zobrazeno 1 - 10 of 59 pro vyhledávání: '"de la Haba-Rodríguez JR"'
1
Akademický článek
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
Autor: de la Haba-Rodríguez JR; Medical Oncology Department, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universi-tario Reina Sofía, Universidad de Córdoba, Av. Menendez Pidal, S/N, Córdoba, 14004, Spain. juahaba@gmail.com.; GEICAM Spanish Breast Cancer Group, Madrid, Spain. juahaba@gmail.com.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. juahaba@gmail.com., Mínguez P; Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM) Madrid, Madrid, Spain.; Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM) Madrid, Madrid, Spain.; Center for Biomedical Network Research On Rare Diseases (CIBERER), ISCIII, Madrid, Spain., Rojo F; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Pathology Service, Hospital Universitario Fundación Jiménez Díaz Madrid, Madrid, Spain., Martín M; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medical Oncology, Medicine Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain., Alba E; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medical Oncology, Hospitales Universitarios Regional y Virgen de La Victoria Málaga, Malaga, Spain.; Clinical and Translational Research, Instituto de Investigación Biomédica de Málaga (IBIMA) Málaga, Malaga, Spain., Servitja S; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medical Oncology, Hospital del Mar, Barcelona, Spain., Prat A; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain., Pérez-Fidalgo JA; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medicine Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain., Gavilá J; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain., Morales C; Medical Oncology Department, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universi-tario Reina Sofía, Universidad de Córdoba, Av. Menendez Pidal, S/N, Córdoba, 14004, Spain.; GEICAM Spanish Breast Cancer Group, Madrid, Spain., Rodriguez-Lescure A; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain., Herrero C; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain., Peña-Enriquez R; Medical Oncology Department, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universi-tario Reina Sofía, Universidad de Córdoba, Av. Menendez Pidal, S/N, Córdoba, 14004, Spain., Herranz J; GEICAM Spanish Breast Cancer Group, Madrid, Spain., Hernando C; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medicine Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain., Hernández-Blanquisett A; Instituto de Cáncer, Centro Hospitalario Serena del Mar, Cartagena, Colombia., Guil-Luna S; Medical Oncology Department, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universi-tario Reina Sofía, Universidad de Córdoba, Av. Menendez Pidal, S/N, Córdoba, 14004, Spain., Martinez MT; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medicine Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain., Blanch S; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain., Caballero R; GEICAM Spanish Breast Cancer Group, Madrid, Spain., Martín N; GEICAM Spanish Breast Cancer Group, Madrid, Spain., Pollán M; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Guerrero-Zotano A; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain., Bermejo B; GEICAM Spanish Breast Cancer Group, Madrid, Spain.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain.; Medicine Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain.
Publikováno v: Journal of mammary gland biology and neoplasia [J Mammary Gland Biol Neoplasia] 2024 Nov 08; Vol. 29 (1), pp. 18. Date of Electronic Publication: 2024 Nov 08.
Zobrazit plný text záznamu
2
Akademický článek
A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project.
Autor: Flores-Paco P; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Vargas-Aliaga A; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Guevara MG; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Lopera I; Medical School, University of Cordoba, Cordoba, Spain., Ruiz LR; Radiation Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., López-Herrero M; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Camús JA; Radiation Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., López-González J; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Inga-Saavedra E; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Montero M; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Barneto I; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Gómez-España MA; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Ruiz E; Radiation Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Ruza M; Radiation Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Armenta A; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., Palacios A; Radiation Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain., De La Haba-Rodríguez JR; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain. juahaba@gmail.com.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain. juahaba@gmail.com.; Medical School, University of Cordoba, Cordoba, Spain. juahaba@gmail.com.; Medical Oncology Department, Hospital Universitario Reina Sofía, Av. Menendez Pidal, s/n, 14004, Córdoba, Spain. juahaba@gmail.com., Aranda E; Medical Oncology Department, University Hospital Reina Sofia, Cordoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.; Medical School, University of Cordoba, Cordoba, Spain.
Publikováno v: Journal of neuro-oncology [J Neurooncol] 2024 May; Vol. 167 (3), pp. 407-413. Date of Electronic Publication: 2024 Mar 27.
Zobrazit plný text záznamu
3
Akademický článek
The evolution of S-nitrosylation detection methodology and the role of protein S-nitrosylation in various cancers.
Autor: Liang, Feng1 (AUTHOR), Wang, Min1 (AUTHOR), Li, Jiannan1 (AUTHOR), Guo, Jie2 (AUTHOR) guojie@jlu.edu.cn
Publikováno v: Cancer Cell International. 12/19/2024, Vol. 24 Issue 1, p1-22. 22p.
Zobrazit plný text záznamu
4
Akademický článek
Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
Autor: López-Sánchez LM; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mena R; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Guil-Luna S; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mantrana A; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Peñarando J; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Toledano-Fonseca M; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Conde F; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., De la Haba-Rodríguez JR; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain., Aranda E; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina, Universidad de Córdoba, Córdoba, Spain., Rodríguez-Ariza A; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. antonio.rodriguez.exts@juntadeandalucia.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. antonio.rodriguez.exts@juntadeandalucia.es.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain. antonio.rodriguez.exts@juntadeandalucia.es.
Publikováno v: Laboratory investigation; a journal of technical methods and pathology [Lab Invest] 2021 Mar; Vol. 101 (3), pp. 292-303. Date of Electronic Publication: 2020 Dec 01.
Zobrazit plný text záznamu
5
Akademický článek
Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts.
Autor: Guil-Luna S; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mena R; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain., Navarrete-Sirvent C; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain., López-Sánchez LM; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Khouadri K; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain., Toledano-Fonseca M; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mantrana A; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain., Guler I; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain., Villar C; Unidad de Gestión Clínica de Anatomía Patológica, Hospital Universitario Reina Sofía, Córdoba, Spain., Díaz C; Unidad de Gestión Clínica de Cirugía General y del Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain., Medina-Fernández FJ; Unidad de Gestión Clínica de Cirugía General y del Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain., De la Haba-Rodríguez JR; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain., Aranda E; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain.; Departamento de Medicina, Facultad de Medicina de Córdoba, Universidad de Córdoba, Córdoba, Spain., Rodríguez-Ariza A; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain.
Publikováno v: Frontiers in medicine [Front Med (Lausanne)] 2020 Jul 03; Vol. 7, pp. 264. Date of Electronic Publication: 2020 Jul 03 (Print Publication: 2020).
Zobrazit plný text záznamu
6
Akademický článek
Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer.
Autor: Toledano-Fonseca M; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain.; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain., Cano MT; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Inga E; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Rodríguez-Alonso R; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Gómez-España MA; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain.; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Guil-Luna S; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain.; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain., Mena-Osuna R; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain., de la Haba-Rodríguez JR; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain.; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain.; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Rodríguez-Ariza A; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain.; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain.; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain., Aranda E; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain.; Cancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, Spain.; Medical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, Spain.; Department of Medicine, Faculty of Medicine, University of Córdoba, E14004 Córdoba, Spain.
Publikováno v: Cancers [Cancers (Basel)] 2020 Jul 01; Vol. 12 (7). Date of Electronic Publication: 2020 Jul 01.
Zobrazit plný text záznamu
7
Akademický článek
SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours.
Autor: López-Sánchez LM; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Jiménez-Izquierdo R; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Peñarando J; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Mena R; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Guil-Luna S; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., Toledano M; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Conde F; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Villar C; Unidad de Gestión Clínica de Anatomía Patológica, Hospital Universitario Reina Sofía, Córdoba, Spain., Díaz C; Unidad de Gestión Clínica de Cirugía General y del Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain., Ortea I; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain., De la Haba-Rodríguez JR; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain., Aranda E; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain., Rodríguez-Ariza A; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Publikováno v: Journal of cellular and molecular medicine [J Cell Mol Med] 2019 Dec; Vol. 23 (12), pp. 8219-8232. Date of Electronic Publication: 2019 Sep 27.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.
Autor: Cañas A; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: amandacanasrodriguez@gmail.com., López-Sánchez LM; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: lmlopezsanchez@gmail.com., Peñarando J; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jon_aries80@hotmail.com., Valverde A; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: aracelivalverdeestepa@hotmail.es., Conde F; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: fmcp@usal.es., Hernández V; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: vanessa-septiembre@hotmail.com., Fuentes E; Pathology Department, IMIBIC, Reina Sofía Hospital, University of Córdoba, Spain. Electronic address: elena.fuentes.sspa@juntadeandalucia.es., López-Pedrera C; Research Unit, IMIBIC, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain. Electronic address: rosario.lopez.exts@juntadeandalucia.es., de la Haba-Rodríguez JR; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: juahaba@gmail.com., Aranda E; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: earandaa@seom.org., Rodríguez-Ariza A; Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: antonio.rodriguez.exts@juntadeandalucia.es.
Publikováno v: Biochimica et biophysica acta [Biochim Biophys Acta] 2016 Apr; Vol. 1862 (4), pp. 601-610. Date of Electronic Publication: 2016 Feb 06.
Zobrazit plný text záznamu
10
Akademický článek
Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.
Autor: Moreno-Muñoz D; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., de la Haba-Rodríguez JR; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Conde F; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., López-Sánchez LM; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Valverde A; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Hernández V; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Martínez A; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain.; Clinical Analysis Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain., Villar C; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain.; Pathology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain., Gómez-España A; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Porras I; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Rodríguez-Ariza A; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain., Aranda E; Oncology Department, Maimonides Institute for Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain.
Publikováno v: European journal of clinical investigation [Eur J Clin Invest] 2015 Dec; Vol. 45 (12), pp. 1325-32. Date of Electronic Publication: 2015 Nov 20.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje